Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes.

NCT01931982 · Completed

Last updated 2026-05-28

This clinical trial tests whether a medication called GLP-1 can improve blood flow in the small blood vessels of the heart in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, single-blind treatment study

Participants 20 people

Who can join Ages 25–75 · all sexes

Timeline Started 2013-05 · est. completion 2014-04

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT01931982 ↗

Description as written by the study sponsor.

The purpose of the study is to determine if a GLP-1 agonist improves microvascular perfusion in the heart of patients with type 2 diabetes

Treatments tested

Victoza Drug

Main thing measured	Change in coronary flow reserve (CFR)
Sponsor	Bispebjerg Hospital
Conditions studied	Type 2 Diabetes, Microvascular Dysfunction
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01931982 ↗